Immunogenicity;Incidence of Treatment-Emergent Adverse Events

Immunogenicity;Incidence of Treatment-Emergent Adverse Events

None

Incidence of Treatment-Emergent Adverse Events [ Time Frame: Group A: 6 weeks Group B: 8 weeks ] Frequency and severity of each adverse event solicited local and systemic AEs from the first vaccination to 4 weeks after the second vaccination Immunogenicity [ Time Frame: Group A: Week 7 Group B: Week 9 ] Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody

Immunogenicity;Incidence of Treatment-Emergent Adverse Events

Immunogenicity;Incidence of Treatment-Emergent Adverse Events